FDA Extends Review Period For Ascendis Pharma's TransCon PTH For Adults With Hypoparathyroidism
Portfolio Pulse from Benzinga Newsdesk
The FDA has extended the review period for Ascendis Pharma's TransCon PTH, a treatment for adults with hypoparathyroidism, by three months. The new Prescription Drug User Fee Act (PDUFA) goal date is now set for August 14, 2024.
May 14, 2024 | 6:37 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The FDA's decision to extend the review period for Ascendis Pharma's TransCon PTH could lead to a temporary setback in investor confidence, potentially impacting ASND's stock price in the short term.
Regulatory milestones, such as PDUFA dates, are critical for pharmaceutical companies. Delays in these processes can lead to investor uncertainty regarding the product's market entry timeline, potentially affecting the company's stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100